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PURPOSE. Genetics has made significant contributions to the
study of glaucoma over the past few decades. Cholesterol-24S-
hydroxylase (CYP46A1) is a cholesterol-metabolizing enzyme
that is especially expressed in retinal ganglion cells. CYP46A1
and its metabolic product, 24S-hydroxycholesterol, have been
linked to neurodegeneration. A single-nucleotide polymor-
phism (SNP) in the CYP46A1 gene, designated as rs754203 and
associated with Alzheimer disease, was evaluated as a genetic
risk factor for primary open-angle glaucoma (POAG), as well as
plasma 24S-hydroxycholesterol levels.
METHODS. The frequency of the CYP46*C and CYP46*T alleles
was analyzed in 150 patients with POAG and 118 control
subjects. Plasma 24S-hydroxycholesterol levels were quanti-
fied. Sex, age, alleles, and genotype frequencies between pa-
tients with POAG and control subjects were compared by
using the 2 and Student’s t-tests. Odds ratios (ORs) and 95%
confidence intervals (CIs) were calculated by logistic regres-
sion to assess the relative association between disease and age,
sex, and genotypes.
RESULTS. The frequency of the TT genotype was significantly
higher in patients with POAG than in control subjects (61.3%
versus 48.3%, respectively, OR  1.26; 95% CI  1.006–1.574,
P  0.05). Plasma 24S-hydroxycholesterol levels did not differ
between control subjects and patients with POAG. The ratio of
estimated brain weight to liver volume as an estimate of the
capacity of the human body to synthesize and metabolize
24S-hydroxycholesterol was found to correlate to plasma 24S-
hydroxycholesterol in control subjects and patients with
POAG.
CONCLUSIONS. The rs754203 SNP in CYP46A1 was associated
with a risk for POAG. This polymorphism was not associated
with changes in plasma 24S-hydroxycholesterol, highlighting
that despite its retinal origin, 24S-hydroxycholesterol cannot
be used as a biomarker for POAG. (Invest Ophthalmol Vis Sci.
2009;50:5712–5717) DOI:10.1167/iovs.09-3655
Glaucoma is the second leading cause of blindness world-wide, affecting more than 50 million people.1 Glaucoma is
a progressive optic neuropathy characterized by optic nerve
head changes and visual field loss.2 Improving case identifica-
tion and providing a better understanding of the causes of
glaucoma has brought about great progress in defining risk
factors such as high intraocular pressure, age, familial history,
ethnicity, and myopia, which have been associated frequently
with primary open-angle glaucoma (POAG).3 Genetics has sub-
stantially contributed to the study of glaucoma over the past
few decades. Myocilin has been identified and validated as the
first gene linked to more than 10% of juvenile-onset POAG
cases and 4% of adult-onset POAG cases.4,5 Other genes such as
optineurin, WDR36, and CYP1B1 have been found more fre-
quently in certain clinical presentations of glaucoma. Never-
theless, the link between the genes and the development of the
disease is not always clearly demonstrated.6 Other associations
such as diabetes or systemic hypertension are still being de-
bated. The links between dyslipidemia and particularly choles-
terol abnormalities have already been described.7 Recent stud-
ies have reported the efficacy of statins and nonstatin
cholesterol-lowering drugs in the treatment of POAG.8–10 Al-
though the mechanism underlying this association remains
unclear, these data suggest that reducing cholesterol biosyn-
thesis may be a target for POAG treatment. Increasing choles-
terol efflux and/or enhancing cholesterol catabolism may also
be critical.
We11 and others12 recently reported that cholesterol 24S-
hydroxylase (CYP46A1) is exclusively expressed in the neuro-
nal part of the retina, most particularly in retinal ganglion cells.
This finding consistently supports the possible role played by
CYP46A1 in cholesterol homeostasis in ocular structures. Cho-
lesterol-24S-hydroxylase was initially identified as a cholesterol-
metabolizing enzyme in the brain. Therein, it catalyzes the
formation of 24S-hydroxycholesterol, a polar metabolite of
cholesterol that can cross the blood–brain barrier.13–17 In
addition to their role in disease-free conditions, cholesterol-
24S-hydroxylase (CYP46A1) and 24S-hydroxycholesterol have
been linked to neurologic disorders of the central nervous
system18–20 and potentially to neuronal death.19 Single-nucle-
otide polymorphisms (SNPs) have been identified in the
CYP46A1 gene. In some21–32 but not all28,33–39 studies, this
type of polymorphism has been associated with increased risk
for late-onset Alzheimer disease. Surprisingly, whether this
intronic polymorphism affects the P450 mRNA and protein
levels has not yet been studied. Therefore, today the mecha-
nistic relation between the polymorphism and the apparent
effect on the risk of Alzheimer disease remains unknown.
The purpose of this study was to explore the association of
rs754203 SNP in intron 2 of the CYP46A1 gene with the risk of
POAG in a population from a single center in France and to
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evaluate plasma levels of the cholesterol metabolite formed by
CYP46A1 activity, 24S-hydroxycholesterol.
METHODS
Subjects
The protocol adhered to the tenets of the Declaration of Helsinki. This
cross-sectional study was approved by the Ethics Committee of Bur-
gundy (France). Informed consent was obtained from all subjects
before participation.
Blood samples were collected from 150 patients with glaucoma and
118 control subjects after an overnight fast at the Department of
Ophthalmology, Dijon University Hospital, Dijon, France. None of the
subjects was related to any other. All patients included in the study
were examined by a glaucoma specialist and underwent a thorough
ocular examination. The patients had been observed in our clinic for
several years. They did not have a history of neurologic disease or
dyslipidemia. Those with angle-closure glaucomas and secondary glau-
comas were excluded. POAG was defined by an open angle on gonios-
copy, characteristic glaucomatous optic nerve head abnormalities, and
corresponding reliable visual field defects recorded with SITA standard
white-on-white perimetry (Humphrey Field Analyzer HFA-II; Carl Zeiss
Meditec, Paris, France). Among the 150 patients, 18 had normal-
tension glaucoma and four had exfoliative glaucoma. The glaucoma
stages were defined according to the classification of Hoddap et al.40
The control subjects were age matched and recruited among patients
operated on for cataract or lid surgery and willing to participate in the
study. They had an IOP below 21 mm Hg, no evidence of glaucoma on
optic disc examination, and a normal frequency-doubling technique
screening test result. The brain weight and liver volume were calcu-
lated using size and weight data and established formulas from the
literature.41–43
CYP46A1 Genotyping
Buffy coats were placed on DNA-preserving paper (FTA; Whatman,
Kent, UK) and stored at room temperature in the dark according to the
manufacturer’s instructions. A 1.25-mm sample disc was taken for each
PCR reaction. A 285-bp PCR product was amplified by using specific
primers for rs754203 SNP (forward primer: 5-TGAAAACGAGTTTC-
CCGTCC-3; reverse primer: 5-GTGTGACCAGGTAACAGTCA-3) in a
12.5-L volume reaction with 1.25 U of DNA polymerase, 1.5 mM of
MgCl2, 1.25 L of 10 NH4 buffer, 200 M dNTPs (BioTaq; Bioline
GmbH, Luckenwalde, Germany).
After initial denaturation at 95°C for 8 minutes, the reaction mix-
ture was subjected to 50 cycles of 1-minute denaturation at 95°C,
1-minute annealing at 53°C, and a 2-minute extension at 72°C, fol-
lowed by a final extension at 72°C for 5 minutes. The PCR products
were digested by MspI (Promega, Charbonnie`res, France). The frag-
ment amplification and digestion results were revealed by 1.8% agarose
gel electrophoresis and ethidium bromide staining. The CYP46A1*T
allele corresponded to the uncut 285-bp fragment, whereas the
CYP46A1*C allele was characterized by two fragments of 209 and
76 bp.
Quantification of Plasma
24S-hydroxycholesterol Levels
Plasma 24S-hydroxycholesterol levels were assayed by isotope dilution
mass spectrometry using racemic [23,23,24-2H3]-24-hydroxycholes-
terol, as previously described.14,17,18,44 Briefly, deuterated 24-hydroxy-
cholesterol (200 ng, [23,23,24-2H3]-24-hydroxycholesterol) was added
to 0.5 mL of plasma. After alkaline hydrolysis with 1 N KOH in 90%
ethanol for 2 hours, the solution was neutralized with 65 L of
phosphoric acid, and the sterols were extracted with 9 mL of chloro-
form in the presence of 3 mL of 0.9% sodium chloride. The organic
phase was removed, and the solvent was evaporated to dryness. The
sterols were dissolved in 1 mL of toluene. A 100 L aliquot was
removed for quantification of the cholesterol concentration. For this
purpose, 30 g of 5-cholestane was added, the solvents were evap-
orated to dryness, and the sterols were derivatized to trimethylsilyl
ethers by heating at 60°C after the addition of 200 L of pyridine and
200 L of BSTFA (Supelco, Bellafonte, PA). The solvents were evapo-
rated under nitrogen gas, and the samples were resuspended in hexane
and analyzed on a gas chromatography-electron ionization mass spec-
trometer (HP6890 series II; Agilent, Palo Alto, CA) plus a chromato-
graph combined with a mass selective detector (HP; Agilent) operated
in selected ion monitoring mode. A 1-L aliquot was injected by
automated injection in a splitless mode at an injection temperature of
300°C on a fused silica capillary column (30 m 0.25 mm ID; 0.25 m
film thickness; DB-5MS; J&W Scientific, Agilent Technologies, Massy,
France). The initial oven temperature was kept at 50°C for 1 minute;
then it was increased at a rate of 20°C  min1 to 250°C and thereafter
at 5°C  min1 to a final temperature of 300°C. The temperature of the
transfer line was kept at 300°C. Electron impact ionization was used at
70 eV ionization energy. Trimethylsilyl-cholesterol and 5-cholestane
were measured at m/z 368 and 372 atomic mass units (amu), respec-
tively. Absolute amounts of cholesterol were determined by interpola-
tion from a standard curve generated in each experiment.
The remainder of the saponified sterols was purified on silica
columns (Supelco) for quantification of 24S-hydroxycholesterol. Cho-
lesterol was eluted with 8 mL of 0.5% isopropanol in hexane. Purified
oxysterols were subsequently eluted with 5 mL of 30% isopropanol in
hexane and derivatized to trimethylsilyl ether as just described. The
samples were analyzed by gas chromatography-mass spectrometry as
described. Both 24S-hydroxycholesterol and deuterated 24-hydroxy-
cholesterol were measured at m/z 413 and 416 amu, respectively.
Absolute amounts of 24S-hydroxycholesterol were determined by in-
terpolation from a standard curve generated in each experiment. A
typical mass spectrometry-gas chromatogram obtained from a plasma
sample is displayed in Figure 1, as well as a typical standard curve in
the inset in Figure 1.
Statistical Analysis
The Student’s t-test and the 2 test were performed to compare sex,
age, alleles, and genotype frequencies between POAG cases and con-
trols. Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated by logistic regression analysis to assess the relative associa-
tion between disease and age, sex, and genotypes. The percentage of
population-attributable risk of carrying the TT genotype was calculated
with the formula f(R  1)/R, where f is the fraction of cases with the
TT-genotype and R is the measure of OR. The SAS Software (SAS
Institute, Cary, NC) was used for statistical analysis. P  0.05 was
considered to be statistically significant.
RESULTS
The clinical characteristics of control subjects and patients
with POAG are presented in Table 1. Both groups were similar
except for the female-to-male ratio in moderate POAG com-
pared with control subjects and other POAG subgroups (Table
1). The genotypic OR and 95% CI for POAG were estimated
assuming a dominant genetic model (major TT homozygote
versus the others). The frequency of the TT-genotype and
T-allele in the CYP46A1 intron 2 rs754203 polymorphism was
significantly higher in the population of patients with POAG
than in the control group: 61.3% versus 48.3%, respectively, for
the TT genotype (P  0.05). This frequency was even greater
in patients with normal-tension glaucoma since 13 of the 18
carried the TT genotype. The rs754203 SNP in intron 2 of
CYP46A1 was associated with a significant risk for POAG
(OR  1.26; 95% CI  1.006–1.574, P  0.05, Table 1).
Patients with POAG had no significant differences in plasma
24S-hydroxycholesterol levels and the 24S-hydroxycholesterol-
to-cholesterol ratio compared with control subjects (P  0.05,
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Table 1). Similarly, the plasma 24S-hydroxycholesterol levels
and the 24S-hydroxycholesterol-to-cholesterol ratio were not
different between CC, CT, and TT carriers when considering
patients with POAG and control subjects independently (P 
0.05, Table 2) or together (P  0.05, data not shown). Plasma
absolute and cholesterol-related 24S-hydroxycholesterol levels
did not correlate to visual field parameters such as MD (mean
defect) or PSD (pattern standard deviation) (data not shown).
The subjects’ ages, corresponding to the age when blood was
sampled, were used as the cofactor. Figure 2 shows the plasma
cholesterol-related levels of 24S-hydroxycholesterol in control
subjects (Fig. 2A) and patients with POAG (Fig. 2B) from the
age of 44 years onward. The ratio between brain weight and
liver volume for the different ages, based on data from the
literature,41–43 is also indicated in the figure. The levels of
24S-hydroxycholesterol closely followed the brain weight-to-
liver volume ratio during the different decades of life. The only
exception was observed in patients with POAG older than 80
years who had lower plasma 24S-hydroxycholesterol levels
than expected from their brain weight-to-liver volume ratio.
DISCUSSION
Glaucoma encompasses a group of diseases that appear to be
genetically heterogeneous. Different glaucoma genes have
been identified, but these genes account for only a small
proportion of glaucomas.45 Myocilin mutations have been
linked to POAG and associated with 10% of juvenile-onset and
4% of adult-onset cases of POAG.4,5 Nevertheless, contradic-
tory data have been obtained on other genes such as apoli-
poprotein E.46–56 Most glaucoma cases appear to be multifac-
torial and are probably affected by multiple interacting loci.
Several genetic susceptibility factors have been suggested to
contribute to glaucoma. These factors fit into two broad
groups, those affecting intraocular pressure and those that are
important in modulating retinal ganglion cell viability.45 Recent
data suggest that cholesterol and cholesterol metabolism may
be involved in the pathogenesis of glaucoma.8,9,57 Cholesterol-
24S-hydroxylase (CYP46A1) is a cholesterol-metabolizing en-
zyme involved in the removal of cholesterol from neuronal
structures.13,14,17 Among various SNPs in the CYP46A1
FIGURE 1. Typical trace obtained by
gas chromatography-mass spectrom-
etry for quantification of 24S-hy-
droxycholesterol in a human plasma
sample using an internal deuterated
standard of 24-hydroxycholesterol.
Inset: a standard curve.
TABLE 1. Clinical Characteristics, Plasma 24S-Hydroxycholesterol Levels and SNP in Intron 2 of the CYP46A1 Gene in the Study Subjects
Control
Subjects
Patients with POAG
All Early* Moderate* Advanced*
n 118 150 31 49 70
Female-male ratio 1.3 1.1 1.1 1.6 0.9
Age, y (mean  SEM) 70.9  1.1 69.5  1 66.1  0.9 68.4  0.9 71.5  1
Plasma 24S-hydroxycholesterol
ng  mL of plasma1 (mean  SEM) 97.4  3.7 94  2.6 102.8  3.2 92.1  2.5 91.5  2.5
ng  mg of cholesterol1 (mean  SEM) 123.1  5.1 126  5.6 120.6  4.9 124.6  5.7 129  5.8
rs754203 SNP in CYP46A1 gene (percentage
of total samples in each category)
CC 2.5 3.3 3.2 4.1 2.9
CT 49.2 35.3 29 42.9 32.9
TT 48.3 61.3 67.7 53.1 64.3
Allele frequency
CYP46A1*C 0.27 0.19 0.18 0.26 0.19
CYP46A1*T 0.73 0.81 0.82 0.74 0.81
* Stages of glaucoma were defined according to the classification of Hoddap et al.40
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gene,21–39,58 the TT genotype in intron 2 of CYP46A1, desig-
nated as rs754203 SNP, has been found to be a risk factor for
Alzheimer disease.25,26,30,32 Several observations have sug-
gested a possible relationship between Alzheimer disease and
glaucoma,47,59–63 with possible pathogenic similarities. Among
the common features of these two diseases are overproduction of
Alzheimer-A peptide, which has been reported in the aqueous
humor of patients with glaucoma,64 and deposition of which has
been associated with retinal degeneration.65 Brown et al.66 re-
ported that 24S-hydroxycholesterol inhibits A and amyloid pre-
cursor protein secretion in cortical neurons via LXR activation.
Increased 24S-hydroxycholesterol production would therefore be
expected to decrease neuron degeneration.
Most 24S-hydroxycholesterol in human circulation origi-
nates from the brain14,17 and is metabolized in the liver.14,67
Hence, the ratio of brain weight-to-liver volume has been found
to be a powerful indicator of the age-related variations of
plasma 24S-hydroxycholesterol levels in humans.18 In our pop-
ulation of patients with POAG and control subjects, we also
found a correlation between plasma 24S-hydroxycholesterol
and subject age (Fig. 2), suggesting that even though the neural
retina also expresses CYP46A1 and is enriched in 24S-hydroxy-
cholesterol,11 it accounts for only a minor part of the plasma
24S-hydroxycholesterol levels. Furthermore, our data showed
that 24S-hydroxycholesterol was not a relevant glaucoma bio-
marker.
The biological importance of 24S-hydroxycholesterol in the
eye has not been clearly elucidated until now. We11 and oth-
ers12 have found that the neural retina exclusively expresses
CYP46A1 and is enriched in 24S-hydroxycholesterol.11 Of
note, Ikeda et al.68 reported the existence of an enzyme in the
nonpigmented ciliary epithelium capable of converting 24S-
hydroxycholesterol into 7,24S-dihydroxycholesterol. 24S-hy-
droxycholesterol may also bind oxysterol-binding protein,
which has already been reported to be expressed in the reti-
na,69 and thereby participate in cellular signaling. As in the
brain,13,14,17 production of 24S-hydroxycholesterol may be
considered a metabolic pathway for neurons to eliminate cho-
lesterol. Indeed, by triggering the addition of a hydroxyl group,
CYP46A1 renders the cholesterol molecule more hydrophilic
and facilitates its flux through biological membranes. Based on
data from animal models and human observations, other mech-
anisms involving lipoproteins are also crucial for cholesterol
metabolism in the retina.70–74
In view of the present controversy with respect to the
possible link between the intronic polymorphism in the
CYP46A1 gene and Alzheimer disease,21–31,33–39 it is important
that the results of the present study be confirmed in other
populations of patients with glaucoma. Indeed, glaucoma can
be considered an optic nerve neuropathy characterized by
neurodegenerative processes.2 But among the various subtypes
of glaucoma, normal-tension glaucoma may share the closest
TABLE 2. 24S-hydroxycholesterol Levels as a Function of rs754203 SNP in Intron 2 of the CYP46A1
Gene in Control Subjects and Patients with POAG
Plasma 24S-hydroxycholesterol
Age (y)ng  mL plasma1 ng  mg cholesterol1
Control subjects (n  118) 97.4  3.7 123.1  5.1 70.9  1.1
TT (n  57) 104  6.6 123  7.5 71.2  1.6
CCCT (n  61) 91  3.5 123.2  6.7 71  1.4
All POAG patients 94.2  2.6 124.8  5.5 69.5  0.9
TT (n  92) 98.3  3.4 123.7  6.9 68  1.2
CCCT (n  58) 87.9  3.1 126.5  9.7 68.2  1.6
Classified in early glaucoma* 103.4  1.3 122.8  11.1 66.3  0.4
TT (n  21) 106.8  9.8 126.35  14.6 65.2  2.3
CCCT (n  10) 94.9  7.2 109.15  15.6 67.8  3.7
Moderate glaucoma* 92.1  2.1 124.6  10 68.3  1.6
TT (n  26) 96.8  6.9 127.7  14.1 70.3  2.1
CCCT (n  23) 86.9  5.1 121.2  14.5 66  2.3
Advanced glaucoma* 91.4  4.6 128.9  8.5 71.5  1.2
TT (n  45) 94.4  5 122.4  9.9 72.2  1.8
CCCT (n  25) 86.5  4.9 139.9  15.7 70.2  2.7
Results are expressed as the mean  SEM.
* Stages of glaucoma were defined according to the classification of Hoddap et al.40
FIGURE 2. Plasma cholesterol-related
24S-hydroxycholesterol levels in nor-
mal subjects (A) and patients with
POAG (B) as a function of age. Results
are expressed as the mean  SEM.
Estimated ratio between brain weight
and liver volume is indicated.
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features with Alzheimer disease. Therefore, further investiga-
tions of CYP46 polymorphisms in those patients are warranted
to verify the higher frequency of the TT genotype. Since we did
not find a correlation between the levels of 24S-hydroxycho-
lesterol in the circulation and the polymorphism, we do not
have a mechanistic explanation for the apparent link between
glaucoma and the polymorphism. If the present results can be
confirmed, however, the polymorphism can be added as an
additional risk factor for the disease.
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